Last quote by Larry Biegelsen
With the accretion from Actelion, more measured impact from biosimilar competition than expected, solid performance of key drugs and a pipeline that is coming to fruition, we believe that JNJ is poised to reaccelerate its top-line growth. Our analysis of IMS data, Nielsen report and FX trend suggests potential upside in Q3 sales, although the near-term impact of the recent hurricanes makes it hard to handicap any EPS upside.feedback
Oct 09 2017
The latest quote from Larry Biegelsen is: “We could see the company overachieve its cost savings targets. FX tailwind may be closer to 100 basis points, which would translate to additional sales of $500 million.”. It comes from the J&J shares upgraded by Wells Fargo, who says the third quarter was 'turning point' for stock article. You’ll find on this page 2 articles with Larry Biegelsen quoted on topics such as jnj and revenue. Larry Biegelsen has been quoted 3 times in 2 articles.
Take our quote verification challenge and find out !
Quotes by Larry Biegelsen
Oct 09 2017
We could see the company overachieve its cost savings targets. FX tailwind may be closer to 100 basis points, which would translate to additional sales of $500 million.feedback
Jan 26 2017
We are downgrading shares of JNJ ... given the disappointing 2017 revenue guidance the company provided on 1/24. We believe JNJ's overall growth will decelerate significantly in 2017 due to headwinds in its pharma business.feedback
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided